This plasmid gene therapy can restore youthful levels of GHRH hormone to compensate for aging. By the time a person is 70 years old, GHRH levels are roughly 20% of a 20 year old. GHRH has direct effects, particularly on health of the cardiac muscle. It also stimulates release of growth hormone, but through normal mechanisms, and doesn’t result in the overdose effects that can occur in HGH supplementation.
GHRH plasmid gene therapy has been as good as antibiotics at preventing infection in cattle, and it has helped dogs receiving cancer chemotherapy treatment. GHRH plasmid gene therapy has treated kidney failure. GHRH plasmid gene therapy improves ability to withstand heat stress, and its supplementation improves cognition.
A GHRH molecule has an 8-12 minute half-life in the bloodstream, which makes it a difficult hormone to supplement. Thus, it is an excellent candidate for plasmid gene therapy, because with plasmid gene therapy, the hormone is produced continually.
For AIDS treatment, it is little known, but gp120, the HIV attachment protein has high affinity for Growth Hormone Releasing Hormone (GHRH). If all that happens is that GHRH is scavenged from the body, something like rapid aging occurs, and an immune system depression. It was learning this that initially started Dr. Hanley looking into GHRH gene therapy for treatment of HIV/AIDS.
By no means is GHRH depression the singular cause of AIDS. However, it’s probably a significant part of it.